Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros : to Present at the BofA 2021 Napa BioPharma Virtual Conference

06/09/2021 | 05:01pm EDT

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual Conference next week. The fireside chat with Bank of America analyst, Geoff Meacham, PhD, is scheduled for Tuesday, June 15, 2021 at 4:30 p.m. EDT.

The presentation will be webcast. The live and archived webcasts can be accessed at https://investor.omeros.com/upcoming-events. The archived webcast will be available for 30 days.

About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases (e.g., complement-mediated diseases and cancers) and central nervous system disorders. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company’s PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros’ pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors. For more information about Omeros and its programs, visit www.omeros.com.


© Business Wire 2021
All news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
More news
Financials (USD)
Sales 2021 107 M - -
Net income 2021 -128 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -7,30x
Yield 2021 -
Capitalization 904 M 904 M -
EV / Sales 2021 10,8x
EV / Sales 2022 6,96x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 14,50 $
Average target price 27,00 $
Spread / Average Target 86,2%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION1.51%904
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 296